Indivior Pharmaceuticals, Inc. Revenue
Indivior Pharmaceuticals, Inc. (INDV) reported Revenue of $343.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $343.00M, a 13.58% increase year-over-year.
- Indivior Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $317.00M, a 19.17% increase year-over-year.
- Indivior Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $358.00M, a 19.73% increase year-over-year.
- Indivior Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $314.00M, a 2.28% increase year-over-year.
- Indivior Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.24B, a 4.29% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $1.19B, a 8.69% increase from fiscal 2023.
- Indivior Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $1.09B, a 21.31% increase from fiscal 2022.
- Indivior Pharmaceuticals, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $901.00M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $343.00M 10-Q · filed 2026-08-03 | $660.00M 10-Q · filed 2026-08-03 | $1.02B derived: sum of 3 quarters · filed 2026-08-03 | $1.33B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $317.00M 10-Q · filed 2026-04-30 | $675.00M derived: sum of 2 quarters · filed 2026-04-30 | $989.00M derived: sum of 3 quarters · filed 2026-04-30 | $1.29B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $358.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $672.00M derived: sum of 2 quarters · filed 2026-02-26 | $974.00M derived: sum of 3 quarters · filed 2026-08-03 | $1.24B 10-K · filed 2026-02-26 |
| 2025-09-30 | $314.00M 10-Q · filed 2025-10-30 | $616.00M derived: sum of 2 quarters · filed 2026-08-03 | $881.00M 10-Q · filed 2025-10-30 | $1.18B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $302.00M 10-Q · filed 2026-08-03 | $568.00M 10-Q · filed 2026-08-03 | $867.00M derived: sum of 3 quarters · filed 2026-08-03 | $1.17B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $266.00M 10-Q · filed 2026-04-30 | $565.00M derived: sum of 2 quarters · filed 2026-04-30 | $872.00M derived: sum of 3 quarters · filed 2026-04-30 | $1.17B derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $299.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $606.00M derived: sum of 2 quarters · filed 2026-02-26 | $905.00M derived: sum of 3 quarters · filed 2026-02-26 | $1.19B 10-K · filed 2026-02-26 |
| 2024-09-30 | $307.00M 10-Q · filed 2025-10-30 | $606.00M derived: sum of 2 quarters · filed 2025-10-30 | $889.00M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $299.00M 10-Q · filed 2025-07-31 | $583.00M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $284.00M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $1.09B 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $901.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |